BG101781A - Твърд препарат, съдържащ активно вещество - Google Patents

Твърд препарат, съдържащ активно вещество

Info

Publication number
BG101781A
BG101781A BG101781A BG10178197A BG101781A BG 101781 A BG101781 A BG 101781A BG 101781 A BG101781 A BG 101781A BG 10178197 A BG10178197 A BG 10178197A BG 101781 A BG101781 A BG 101781A
Authority
BG
Bulgaria
Prior art keywords
active substance
preparation containing
solid preparation
containing active
preparation
Prior art date
Application number
BG101781A
Other languages
Bulgarian (bg)
English (en)
Inventor
Sven Grabowski
Joerg Breitenbach
Joerg Rosenberg
Axel Sanner
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG101781A publication Critical patent/BG101781A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
BG101781A 1995-02-14 1997-07-17 Твърд препарат, съдържащ активно вещество BG101781A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19504832A DE19504832A1 (de) 1995-02-14 1995-02-14 Feste Wirkstoff-Zubereitungen
PCT/EP1996/000417 WO1996025151A1 (de) 1995-02-14 1996-02-01 Feste wirkstoff-zubereitungen

Publications (1)

Publication Number Publication Date
BG101781A true BG101781A (bg) 1998-03-31

Family

ID=7753890

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101781A BG101781A (bg) 1995-02-14 1997-07-17 Твърд препарат, съдържащ активно вещество

Country Status (25)

Country Link
US (1) US5939099A (cs)
EP (1) EP0809488B1 (cs)
JP (1) JP4049810B2 (cs)
KR (1) KR19980702193A (cs)
CN (1) CN1177584C (cs)
AT (1) ATE220541T1 (cs)
AU (1) AU4786096A (cs)
BG (1) BG101781A (cs)
BR (1) BR9606957A (cs)
CA (1) CA2211033C (cs)
CZ (1) CZ239497A3 (cs)
DE (2) DE19504832A1 (cs)
DK (1) DK0809488T3 (cs)
ES (1) ES2180738T3 (cs)
FI (1) FI973320A7 (cs)
HU (1) HUP9702424A3 (cs)
IL (1) IL117112A0 (cs)
NO (1) NO973730D0 (cs)
NZ (1) NZ302243A (cs)
PL (1) PL321755A1 (cs)
PT (1) PT809488E (cs)
SK (1) SK104397A3 (cs)
TR (1) TR199700786T1 (cs)
WO (1) WO1996025151A1 (cs)
ZA (1) ZA961137B (cs)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DE19536387A1 (de) * 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
JP3572213B2 (ja) * 1999-01-18 2004-09-29 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
JP2000327701A (ja) * 1999-05-18 2000-11-28 Shin Etsu Chem Co Ltd 低置換度ヒドロキシプロピルセルロース及び固形製剤
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
BR0013488A (pt) 1999-08-24 2002-05-07 Siemens Ag Equipamento de aspiração para um motor de combustão interna
TR200200763T2 (tr) * 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
JP2004525109A (ja) * 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
AU2003263162B2 (en) 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006518380A (ja) * 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20080293801A1 (en) * 2003-11-14 2008-11-27 Pfizer Inc. Solid Amorphous Dispersions of An Mtp Inhibitor For Treatment of Obesity
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
TW200539903A (en) 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
KR101482922B1 (ko) * 2004-08-12 2015-01-15 레킷트 벵키저 헬스케어(유케이)리미티드 용융 압출에 의해 제조된, nsaid와 당 알콜을 포함하는 과립
EP1969940A3 (en) 2004-12-17 2008-12-10 Devgen NV Nematicidal compositions
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ585116A (en) * 2005-05-10 2011-12-22 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds e.g. metformin hydrochloride
CN101484142B (zh) 2006-03-24 2013-06-05 奥克思利尤姆国际控股公司 包含对碱性不稳定的药物的稳定组合物
CN101489756B (zh) * 2006-03-24 2013-08-07 奥克思利尤姆国际控股公司 热熔挤出层压材料的制备方法
US20090258953A1 (en) * 2006-06-07 2009-10-15 Basf Se Use of vinyl acetate-sulfonate copolymers as solubilizers for slightly water-solubable compounds
US8343547B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
AU2008274352B2 (en) * 2007-07-06 2014-01-16 Basf Se Use of homo- and copolymers for stabilizing active ingredient formulations
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2219624A2 (en) 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
PL2280704T3 (pl) * 2008-03-31 2015-10-30 Cymabay Therapeutics Inc Związki oksymetylenoarylowe i ich zastosowania
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
JP2012502883A (ja) * 2008-06-13 2012-02-02 グラクソ グループ リミテッド 医薬製剤
PT2309987E (pt) * 2008-07-03 2012-12-13 Novartis Ag Processo para granulação por fusão
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012085236A1 (en) 2010-12-23 2012-06-28 Abbott Gmbh & Co. Kg Solid retard formulations based on solid dispersions
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法
EP2688555B1 (de) * 2011-03-21 2017-11-01 Sanofi-Aventis Deutschland GmbH Feste ambroxolhaltige zubereitung
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
LT2838512T (lt) 2012-04-18 2018-11-12 Grünenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9833409B2 (en) * 2012-11-27 2017-12-05 Dsm Ip Assets B.V. Process for the production of discrete solid extruded particles
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
CN105283203B (zh) * 2013-06-03 2018-12-28 信越化学工业株式会社 用于热熔挤出的组合物以及通过使用该组合物制备热熔挤出物的方法
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105744847A (zh) * 2013-11-15 2016-07-06 帝斯曼知识产权资产管理有限公司 通过热熔挤出获得的略溶化合物的制剂
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
CU24395B1 (es) 2014-03-17 2019-04-04 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US11278046B2 (en) 2015-10-07 2022-03-22 Dsm Ip Assets B.V. Multivitamin extrudates
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018115130A1 (en) 2016-12-23 2018-06-28 Hermes Arzneimittel Gmbh Oral pharmaceutical composition with improved taste-masking properties
SG10202110112TA (en) 2017-03-10 2021-10-28 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Nash/nafldおよび関連疾患の治療のための組合せ
AU2020260018A1 (en) 2019-04-19 2021-11-04 Pfizer Inc. Anti-proliferative agents for treating PAH
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なbckdk阻害剤としての5-(チオフェン-2-イル)-1h-テトラゾール誘導体
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶2 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Nafld/nashおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
IL312296A (en) 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
US12637461B2 (en) 2022-10-18 2026-05-26 Pfizer Inc. Compounds for the activation of AMPK
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
DE59103470D1 (de) * 1990-06-13 1994-12-15 Ciba Geigy Ag Verfahren zum Überprüfen des Gelierprozesses nach dem Giessen eines reaktiven Harzsystems in eine Produktionsform.
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
JPH05139974A (ja) * 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンa物質含有易溶性固体分散体の製造法
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
DK0809488T3 (da) 2002-09-02
ZA961137B (en) 1997-09-16
JPH10513477A (ja) 1998-12-22
SK104397A3 (en) 1998-04-08
EP0809488A1 (de) 1997-12-03
PL321755A1 (en) 1997-12-22
TR199700786T1 (xx) 1998-02-21
JP4049810B2 (ja) 2008-02-20
EP0809488B1 (de) 2002-07-17
HUP9702424A3 (en) 2001-03-28
AU4786096A (en) 1996-09-04
CN1177584C (zh) 2004-12-01
IL117112A0 (en) 1996-06-18
ATE220541T1 (de) 2002-08-15
HUP9702424A2 (hu) 1998-06-29
BR9606957A (pt) 1997-10-28
DE19504832A1 (de) 1996-08-22
CZ239497A3 (cs) 1998-01-14
CN1174503A (zh) 1998-02-25
PT809488E (pt) 2002-11-29
ES2180738T3 (es) 2003-02-16
FI973320L (fi) 1997-10-13
FI973320A0 (fi) 1997-08-13
KR19980702193A (ko) 1998-07-15
US5939099A (en) 1999-08-17
FI973320A7 (fi) 1997-10-13
WO1996025151A1 (de) 1996-08-22
NO973730L (no) 1997-08-13
DE59609451D1 (de) 2002-08-22
CA2211033A1 (en) 1996-08-22
NZ302243A (en) 1999-01-28
NO973730D0 (no) 1997-08-13
CA2211033C (en) 2005-04-26

Similar Documents

Publication Publication Date Title
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
AU697005B2 (en) Implantable molded articles for the administration of active substances to plants
ATE213405T1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
AU4718496A (en) Use of aerogels in agriculture
GEP20002331B (en) Alkylated Raphamicine Derivatives
DK524187D0 (da) Aminosyrechelaterede midler til udlevering til specifikke biologiske vaevssteder
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
AU7495596A (en) Process for the production of morphologically uniform microcapsules and microcapsules that are produced according to this process
ATE146360T1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE69738961D1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
DE69412250D1 (de) Pyridobismidazole enthaltendes rigid-rod-Polymer
EP1221326A3 (en) Nitric oxide donors capable of reducing toxicity from drugs
EP0191133A3 (en) Stable salts of sam with polyanions
EG18379A (en) Novel pharmacological compounds
PL321755A1 (en) Soil preparations of active substances
NZ510254A (en) Novel composition and use
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
ES8800605A1 (es) Procedimiento para preparar una composicion coloeada de utilidad en cirugia ocular.
BG102362A (en) New derivatives of amino acids, their preparation and application
FI962354A0 (fi) Pitkävaikutteisia ruiskesuspensioita ja menetelmä niiden valmistamiseksi
DE60001744D1 (de) Stabilisator für arzneimittel